drugset / Trial / NCT03703492
Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
Phase 2
Completed
12 enrolled
University of Wisconsin, Madison
National Cancer Institute (NCI) · collabNational Center for Advancing Translational Sciences (NCATS) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This prospective, one-arm study which will enroll participants with biopsy-proven DCIS scheduled for diagnostic breast MRI for preoperative staging/extent of disease evaluation as part of standard of care. Eligible participants will be consented for participation in the research study which includes a directed breast PET/MRI with 18F-FES. 18F-FES uptake of the known malignancy will be measured on the PET/MRI examination using standardized uptake values (SUV) and tumor-to-normal tissue ratios.
Timeline
- Start
- 2019-01-03
- Primary completion
- 2024-01-02
- Completion
- 2024-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F-18 16 Alpha-Fluoroestradiol | Diagnostic / imaging agent | — | Other |
| Background | Gadobenate dimeglumine | Diagnostic / imaging agent | — | Intravenous |